Extractable thesis: "Keystone gut bacteria — strict anaerobes that die on contact with oxygen and cannot be delivered as live cells — produce a broad repertoire of beneficial metabolites and signals beyond butyrate; Trilliome's approach is to induce these species in situ using shelf-stable plant-derived bioactives."

The problem with delivery

The bacteria with the strongest links to cognitive and metabolic health — keystone gut species — are strict anaerobes. They die on contact with oxygen, which means they cannot survive manufacturing, packaging, or shelf life. The "next-generation probiotics" built on them are usually pasteurised dead cells. And conventional prebiotic fibres try to feed the gut indiscriminately, at 5–10 gram doses, with no species selectivity.

There's a third way: leave the bacteria where they are, and switch them on.

Activation, not addition

TRI-01 is a plant-derived bioactive that selectively induces a named four-species consortium of keystone species already resident in the human gut:

  • Agathobaculum butyriciproducens
  • Coprococcus catus
  • Anaerostipes hadrus
  • Faecalibacillus intestinalis

Because it acts on bacteria already present, there's no viability problem and no cold chain — and because it's selective, it works at a small, precise dose rather than by bulk feeding.

Why these species

These four are keystone species — disproportionately important to a healthy gut ecosystem. They produce a broad repertoire of beneficial molecules across three distinct routes. Butyrate is part of the story, not the whole of it.

  • Immune and inflammatory control. Short-chain fatty acids act on immune signalling in the gut wall, calibrating the inflammatory tone that underlies much of age-related decline.
  • Metabolic signalling. Coprococcus catus and Anaerostipes hadrus generate propionate through pathways separate from butyrate. Propionate acts on the enteroendocrine receptors governing GLP-1 and PYY release, the axis behind appetite and glucose regulation. This is a distinct route, not a subset of the butyrate story.
  • Neuroactive output. Coprococcus catus produces DOPAC, a dopamine metabolite; short-chain fatty acids also reach the brain directly and through vagal afferent signalling.

The lead species, Agathobaculum butyriciproducens, stands out for exactly this reason. In peer-reviewed mouse-model studies it has been associated with reduced amyloid-β plaque burden and cognitive improvement (Lee et al., 2020), dendritic-spine maturation and synaptogenesis (Song et al., 2024), and dopaminergic neuroprotection (Bok et al., 2022) — a capacity to modulate neuroinflammation that butyrate alone doesn't explain, and that typical butyrate-producers don't share. These are published findings about the species — the bridge to human benefit requires clinical evidence, which is the focus of our program (see the evidence).

The same logic, a second way: TRI-04

Where TRI-01 induces specific species directly, TRI-04 — a low-molecular-weight prebiotic fibre — nourishes the broader community of butyrate-producing bacteria as a clean, water-soluble substrate. The butyrate it helps produce feeds the same metabolic signalling, including the butyrate → GLP-1 pathway now central to metabolic-health science. (A claim path under study; see TRI-04.)

From mechanism to map

Both products come out of the same engine — Teroka — which learns, across the gut ecosystem, which bioactives and combinations move which species and metabolites. Mechanism isn't a one-off discovery here; it's what the platform is built to find, at scale. How the platform works →

FAQ

  • Why can't you just put these bacteria in a probiotic? They're strict anaerobes — they die on contact with oxygen and can't survive manufacturing or shelf life.
  • What does "activation" mean? Inducing beneficial species already present in the gut, rather than delivering live cells or bulk substrate.
  • Is this just about butyrate? No. Butyrate is one beneficial output; these keystone species also produce neuroactive and immunomodulatory factors, and Agathobaculum butyriciproducens in particular has a published capacity to modulate neuroinflammation that butyrate alone doesn't explain.
  • Which species does TRI-01 target? A named four-species consortium: Agathobaculum butyriciproducens, Coprococcus catus, Anaerostipes hadrus, Faecalibacillus intestinalis.
  • How is this different from a prebiotic fibre like inulin, FOS or GOS? Those are bulk substrates. Bacteria consume them, so the delivered mass sets the effect and the intake runs to grams. A modulator changes what resident species do without being eaten by them, which is why it works at milligrams. (More on /low-dose-actives.)
  • How much goes into a serving? Milligrams, where conventional prebiotic fibres need 5 to 10 grams. The figure for each active is on its own product page.
  • Does it need refrigeration? No. These are plant-derived small molecules with nothing alive in them, so there is no viability to protect and no cold chain. (More on /gut-health-without-live-cells.)